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CASE PRESENTATION
A 35-year-old African-American woman with sickle cell
trait presented to our medical center with severe gross
hematuria. The patient reported having had dark urine for
at least 2 months, but after a recent 2 h and 30 min air
travel, her urine became bright red and she began passing
dark clots. In addition, she started experiencing
generalized fatigue, weakness, and mild dizziness.
The patient had experienced several episodes of gross
hematuria in the past. One such episode, 15 years ago,
resulted in a prolonged hospitalization and transfusion of
5 U of blood. Another episode took place 11 years ago
lasting for approximately 2 weeks, but symptoms resolved
spontaneously. The etiology of her hematuria had never
been established. Other medical problems included
chronic right knee osteoarthritis and degenerative lumbar
disk disease. She denied chronic use of non-steroidal
anti-inflammatory agents, but admitted to frequent use of
acetaminophen for arthritic pain.
Upon presentation, the patient appeared comfortable.
Her blood pressure was 130/60, and heart rate was
80/min. Head, neck, lung, and heart examinations
were unremarkable. The abdomen was soft and
non-tender and liver span was normal. The tip of the spleen
was palpable. There was no pedal edema. Her laboratory
values were significant for mild anemia with hematocrit
of 33% (normal 34–44%). The platelet count was
313 109/l (normal 165–415 109/l) and white blood
cell count was 6.5 109/l (normal 3.5–9.0 109/l). Her
coagulation parameters were normal. The serum
electrolytes were also within normal range. Her renal
function was preserved with a creatinine of 0.9 mg/dl
(normal 0.5–0.9 mg/dl) and a blood urea nitrogen of 7 mg/dl
(normal 7–20 mg/dl). Urine analysis revealed 3þ
hemoglobin and no protein. Urine microscopy showed
182 red blood cells per high powerfield. Urine cultures
were negative. Renal ultrasound measured the
right kidney length at 11.7 cm; the left kidney was
11.9 cm in length; there was no hydronephrosis or calculus
in either kidney. The urinary bladder was unremarkable.
Magnetic resonance imaging confirmed that both kidneys
were of normal size and signal, and no solid enhancing
lesion was identified.
Diagnostic cystoscopy and ureteroscopy were
performed. Blood was visualized effluxing from the right
ureteral orifice. Upon inspection of the collecting system,
the posterior middle pole calyx was found to have a
stenotic infundibulum. Endoinfundibulotomy was
performed to enter the calyx, where there appeared to be
a sloughed ischemic papilla with an accompanying
hemorrhage (Figure 1). The papilla was fully fulgurated in
an attempt to stop the bleeding. The remaining calyces
and the renal pelvis were also inspected and found to be
free of disease. Although the bleeding ceased in the
immediate post-procedure period, it reappeared later
that day.
CLINICAL DIAGNOSIS
Gross hematuria and papillary necrosis related to sickle cell
trait.
CLINICAL FOLLOW-UP
The patient was placed on intravenous fluids and sodium
bicarbonate with concurrent oral furosemide 20 mg twice a
day. Desmopressin acetate (20 mg) was delivered intrave-
nously twice a day for 2 days. Despite this treatment, bleeding
continued. At this point, she was offered a treatment with
intravenous aminocaproic acid, which she refused, but agreed
to angiography with an attempt at embolization. Unfortu-
nately, the angiogram failed to visualize a bleeding vessel and
embolization could not be performed. The patient, although
still bleeding, had a stable hematocrit and vital signs, and
elected to leave the hospital expecting the hematuria to
resolve spontaneously as before. The bleeding resolved
completely 2 weeks after discharge.
DISCUSSION
Sickle cell trait and renal disease
The worldwide prevalence of sickle cell trait is estimated at
5%, with the highest concentration across equatorial Africa,
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where prevalence ranges from 10 to 40%.1 Sickle cell trait
is the most common hemoglobinopathy in the United
States, estimated to be 40–50 times more common than
sickle cell disease, and particularly prevalent among indivi-
duals whose ancestors come from sub-Saharan Africa, India,
Saudi Arabia, and Mediterranean countries. Of 30 400
healthy African-Americans in the metropolitan area of
Washington DC, the overall prevalence of sickle cell trait
was 6.7%.2
Despite the generally benign nature of the sickle cell trait,
several potentially serious complications have been described.
Two important, though rare, non-renal complications
include increased risk of splenic infarction induced by
hypoxia after a high altitude exposure, and increased risk of
sudden death during prolonged physical training or exercise
at high altitude. The latter complication presumably occurs
in association with exertional heat illness and rhabdomyo-
lysis. In addition, patients with sickle cell trait are more prone
to develop several renal complications and these are outlined
in Table 1.
Hematuria is by far the most common complication of
sickle cell trait. Among a large population of male African-
Americans admitted to Veterans Administration hospitals,
the admission rate for hematuria was 4% for patients with
sickle cell trait, which is double of the rate for patients with
normal hemoglobin.3 As the baseline rate of admission for
hematuria in normal male participants was 2%, it is
reasonable to speculate that 50% of the time subjects with
hemoglobin SA would have bleeding unrelated to their sickle
cell trait. Alternative causes of hematuria, such as stones and
lower urinary tract neoplasms, should therefore always be
considered in these patients, and the diagnostic work up
should not be different than evaluation of patients with
normal hemoglobin. Initial testing should include urine
analysis, culture, and cytology; coagulation studies; and renal
ultrasound and/or renal computed tomography (CT) scan. If
sustained gross hematuria is present, cystoscopy with
ureteroscopy may be required. In the case described, two
major causes of gross hematuria were of concern – papillary
necrosis and renal medullary carcinoma (RMC).
Papillary necrosis
Renal papillary necrosis refers to ischemic damage to the
renal medulla and is classically associated with analgesic
abuse, sickle cell disease, and urinary tract infections,
particularly in the setting of diabetes (Table 2). Although
much more common in sickle cell disease, papillary necrosis
is not infrequent in sickle cell trait. It commonly presents
with painless gross hematuria, and may be complicated by
urinary tract infection or obstruction. Bleeding is typically
mild and unilateral. Left kidney involvement is more
frequent, presumably because of its larger size and unique
blood supply. The compression of the left renal vein between
the aorta and the superior mesenteric artery may increase
venous pressure within the left kidney and predispose to
bleeding. Other symptoms occasionally associated with
extensive papillary necrosis include flank pain, abdominal
pain, nausea, and vomiting. Fever, if present, is typically due
to superimposed infection.
Although the exact mechanism of papillary necrosis is not
entirely understood, several factors contributing to this
process have been described. It is well established that
dehydration, acidosis, decreased oxygen tension, and high
osmolarity are the main triggers of red blood cell sickling,
and renal medulla provides all of the above conditions.
Additionally, as the blood flow of the vasa recta is much
slower than in cortical vessels, there is more time for the
hyperosmolar interstitium to draw water out of the red blood
cells, which increases intracellular concentration of sickle cell
hemoglobin and precipitates sickling. This, in turn, increases
the viscosity of blood, which causes even further slowing of
the medullary blood flow. The sluggish flow will ultimately
lead to the formation of microthrombi and result in local
microinfarctions, which directly damage the vasa recta and
reduce their number in the medulla. Loss of the vasa recta
may disrupt the concentration gradient in the medulla and
lead to isosthenuria.
Renal papillary necrosis is difficult to diagnose, especially
if the necrosed papillae remain in situ, but the use of CT and
ultrasound has increased diagnostic yield. Intravenous
pyelogram may be helpful, but it carries risks of iodinated
contrast exposure and, in the case of papillary necrosis, its
superiority to a CT scan has not been clearly established. The
presence of sloughed papillae in the urine is diagnostic, but





Figure 1 | Ureteroscopy findings: (1) small area of possible
mucosal bleeding with intact adjacent papilla, (2) ischemic
papilla, (3) area of active bleeding, and (4) pooled blood within
the calyx.
Table 1 | Renal involvement in sickle cell trait
1 Papillary necrosis (most common)
2 Renal infarction (rare)
3 Loss of concentrating ability, isosthenuria
4 Increased risk of exercise-induced rhabdomyolysis with acute renal
failure
5 Earlier onset of ESRD in patients with autosomal-dominant
polycystic kidney disease
6 Renal medullary carcinoma (extremely rare)
ESRD, end-stage renal disease.
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calyces with ureteroscopy was required to reach the final
diagnosis.
Renal medullary carcinoma
RMC is a rare and highly aggressive tumor, present almost
exclusively in young black individuals with sickle cell trait. In
2003, Dimashkieh et al.4 reviewed 55 cases of RMC reported
in the literature. The average age at tumor presentation was
21 years and the male–female ratio was 2:1. The right kidney
was involved three times more commonly. A total of 50
patients had hemoglobin AS, two patients had hemoglobin
SC, and one patient had hemoglobin SS disease. It has been
postulated that the tumor arises from the epithelium of distal
collecting ducts in the setting of chronic regeneration and
degeneration induced by ischemic damage.
Most tumors can be detected by CT, which typically
reveals a tumor located deep in the renal medulla, infiltrating
the renal pelvis and sinus as well as local structures. On gross
examination, the tumor is poorly circumscribed, lobulated,
and firm with areas of hemorrhage and necrosis. Micro-
scopically, the tumor cells are polymorphic, with large nuclei
and large nucleoli. Satellite lesions involving the cortex are
sometimes found in the venous and lymphatic channels.5
Gene expression analysis of two RMC cases were performed
by Yang et al.6 and a unique molecular signature was observed
compared to the profiles of other renal malignancies.
The most common symptoms at the time of presentation
are flank pain, hematuria, weight loss, and abdominal pain,
but some patients present with cough due to metastatic
involvement of the lungs. The tumor is extremely aggressive
and metastases are present at the time of presentation in most
of the reported cases. All cases reported in the literature
underwent nephrectomy with some receiving chemotherapy
and others immunotherapy. However, none of the treatment
modalities improved the survival and most patients died
within 1 year of diagnosis.7
Treatment of hematuria in sickle cell trait
Many treatments have been reported to affect the clinical
course of hematuria in-patient with sickle cell trait (Table 3).
Because most of the bleeding is self-limited, conservative
management such as bed rest is recommended in all cases.
Other treatments are targeted to eliminate the conditions
predisposing to sickling, but there are no controlled trials
defining the optimal management. Hydration using alkaline
fluids is the treatment used in all patients with sickle cell
crisis and can be used to treat renal complications. It
antagonizes both the dehydration and acidosis, two major
causes of sickling. Some reports have shown improved results
with the use of diuretics along with hydration to increase
urinary flow rate.8
Standard ureterorenoscopy with or without retrograde
pyelography allows for direct visualization of the offending
lesion and often confirms the diagnosis of papillary necrosis.
With the availability of small, flexible ureteroscopes,
ureterorenoscopy has become an excellent means of attempt-
ing to treat bleeding lesions of the urinary tract. Various new
instruments, such as an electrocautery probe, Neodymiu-
m:YAG laser, and Holmium:YAG laser have been used
successfully to treat hematuria due to renal hemangiomas
with minimal complications.9 Although the literature is
currently sparse, a similar approach is frequently being
adapted to treat papillary necrosis in practice. Alternative
ureteroscopic approaches have also been described. For
example, Herard et al.10 reported successful tamponade of
the bleeding with a dilating balloon ureteral catheter under
fluoroscopy. Adequate hemostasis was achieved after the
balloon was inflated for 24 h with a ureteral stent placed
beside it to provide pelvic drainage. In addition, ureteroscopy
proves useful in the management of complications of
papillary necrosis, especially ureteral obstruction from clots
or sloughed papillary bodies.11
If initial management fails, adjuvant pharmacologic agents
may be used. Desmopressin acetate (DDAVPs) decreases
bleeding by means of a dose-dependent increase in plasma
factor VIII and von-Willebrand factor. The most common
mode of administration of desmopressin is by intravenous
infusion, but it may also be given by subcutaneous injection.
A single intravenous infusion at a dose of 0.3 mg/kg of
body weight can be expected to boost the level of factor
VIII three- to sixfold. The peak response is seen approxi-
mately 1 h after completion of the infusion, and tachyphy-
laxis is common with repeated administration. A concen-
trated nasal spray (Octim) has recently become available. A
spray dosage of 300 mg is equivalent to the standard
intravenous dose of 0.3 mg/kg. This form of administration
may prove particularly useful for home treatment of
sustained hematuria.
Baldree et al.12 used desmopressin acetate in sickle
cell trait patients who presented with gross hematuria. Of
the two patients reported in the study, one was also suffering
from mild von-Willebrand factor deficiency and failed
to achieve hemostasis, but hematuria resolved in the
second patient within 18 h of drug infusion. In another
report, a pediatric patient with sickle cell trait and severe
intractable gross hematuria showed a dramatic response to
repeated DDAVP infusion.13 Unfortunately, there are no large
trails of DDAVP use in the management of sustained
hematuria, and more research is needed to establish its
true efficacy.
Table 2 | Conditions commonly associated with renal
papillary necrosis
1 Use of analgesics
2 Diabetes mellitus
3 Urinary tract infection
4 Urinary tract obstruction
5 Sickle cell hemoglobinopathy
6 Renal allograft rejection
7 Renal vein thrombosis
8 Prolonged hypotension, severe dehydration, acidosis, congestive
heart failure, cirrhosis
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Epsilon-aminocaroic acid (EACA, Amicars) is a second
pharmacologic agent commonly used for refractory gross
hematuria. It works as an antifibrinolytic by reversible
binding to plasminogen and inhibiting its activation to
plasmin. As it is concentrated in the urine, the dosage
required to inhibit fibrinolysis in the urinary tract alone is
less than that required to supress plasmin activity in the
blood. Minor side effects have been reported, but one of the
potential complications is the blockage of glomerular
arteries, the renal pelvis, and ureters with undissolved clots.
In 1965, Immergut and Stevenson reported first four cases of
hematuria with sickle cell trait or disease, who responded to
EACA.14 As this original publication, clinical use of EACA
gained popularity and consequently the nephrectomy rates
for refractory hematuria decreased dramatically. The optimal
dose and duration of treatment, however, has not been
studied adequately in sickle cell trait patients. In the largest
retrospective study of EACA efficacy, 26 out of 40 subjects
had hemoglobin SA, seven had hemoglobin SC, and two had
hemoglobin SS.15 The treated subjects (20 out of 40) were
given 6–8 g/day EACA orally divided into 4–6 equal doses. In
some patients, an initial oral or intravenous loading dose of
5 g was also given. As the treated patients on average had
more severe bleeding before admission (15 vs 5 days in
controls), the comparison of two groups is difficult. Never-
theless, after treatment with EACA, the bleeding stopped at a
mean of 2.270.3 days. The frequency of ureteral obstruction
was not different in either group. Another more recent
retrospective study of nine patients with gross hematuria
from various causes showed that treatment with 150 mg/kg/
day in divided oral doses for up to 21 days was effective
without major overt clinical reactions.16
An alternative approach is to inhibit sickling using oral or
intravenous urea loading. Over 30 years ago, the urea has
been demonstrated to inhibit the hydrophobic interaction
between deoxygenated tetramers of hemoglobin S, and thus
to prevent their polymerization.17 Initial clinical application
of this finding led to the treatment of sickle cell crisis with
intravenous urea, targeting blood urea nitrogen level to
150–200 mg/dl range. Despite initial encouraging results, this
strategy was proven ineffective in larger cooperative con-
trolled studies. In 1994, however, Pariser and Katz18 reported
three cases of successful treatment for refractory gross
hematuria in sickle cell trait patients with oral urea. The
patients were treated with 160 g/day of urea divided into four
oral doses, raising blood urea nitrogen close to 100 mg/dl.
Hematuria stopped within 3–4 days, and the blood urea
nitrogen came down to normal levels 2–3 days after cessation
of treatment. Unfortunately, there are no additional reports
or controlled studies evaluating the effectiveness of urea
treatment for hematuria in sickle cell trait.
For intractable cases of urinary bleeding, a more invasive
approach may be required. Renal arteriography with
segmental renal arterial embolization has been used in a
variety of renal structural defects casing hematuria, but in the
case of papillary necrosis the localization of the bleeding renal
segment proves to be extremely difficult. In most reported
cases of papillary necrosis with gross hematuria, including
our case, no focal lesion is apparent on the renal angiogram.
Swartz et al.19 described a case of a sickle cell trait patient
with refractory hematuria and negative renal angiogram,
where bleeding was successfully terminated by segmental
renal infarction using simultaneous ureteroscopy and arter-
iography. In this case, sequential temporary occlusion of the
Table 3 | Treatment of sustained gross hematuria in sickle cell trait patients
Treatment modality Mechanism and comments
Bed rest (inpatients). Exercise avoidance (outpatients) Presumably prevents dislodging of blood clot from the bleeding site and promotes
hemostasis
Hydration (1/2 NS preferred) and alkalinization of
urine
Reverses acidosis, dehydration, and hyperosmolarity thus preventing sickling. No
controlled studies
Diuresis May assist in excretion of sloughed necrotic papillae during hematuria by means of
increased urinary flow. Loop diuretics used in small doses and only in combination with
intravenous fluids. No controlled studies
Blood transfusion Decreases the number of sickling cells. Used only if significant anemia is present
Ureteroscopy with electrocautery, laser treatment, or
balloon tamponade
Confirms the diagnosis and may effectively obliterate local sites of bleeding
Desmopressin (DDAVPs) Increases clotting by dose-dependent increase in plasma factor VIII, and vWF.
Recommended dose: 0.3 mg/kg iv q 12 h 4 doses. Minimal side effects. No controlled
studies
Epsilon-amino caproic acid; EACA (Amicars) Inhibits fibrinolysis by inhibiting plasmin activity. Frequently used as adjuvant to
ureteroscopic treatment. Recommended dose: 3–4 g po or iv three to four times a
day 7–14 days
Oral and intravenous urea Inhibits the polymerization of hemoglobin S. Efficacy for gross hematuria is poorly
studied, therefore generally not recommended
Angiography and embolization Direct blockage of the bleeding vessel. Not very successful. May be combined with
ureteroscopy for improved detection of the bleeding segment
Surgical exploration, segmental nephrectomy, or
radical nephrectomy
Reserved for most severe life-threatening cases. Radical nephrectomy should be avoided
whenever possible. Surgical removal of necrotic tissue and cauterization of bleeding
vessels may occasionally provide adequate hemostasis and spare the kidney
EACA, Epsilon-aminocaroic acid; i.v., intravenous; NS, Normal saline; p.o., per os; vWF, von-Willebrand factor.
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segmental renal arteries with a transcutanous balloon catheter
allowed identification of a bleeding segment by direct
ureteroscopic observation of the cessation of blood flow from
the ureteral orifice. This technique, however, is not routine and
may be difficult to coordinate in most medical centers.
Nephrectomy should be considered as the treatment of last
resort. In addition to the risks of open surgical procedure and
significant loss of nephron mass, one must keep in mind that
hematuria frequently recurs in the contralateral kidney. This
is supposedly because patients with serious hematuria have
involvement of multiple papillae in both kidneys. More
conservative approaches, such us limited segmental nephre-
ctomy, have also been reported as successful after identifica-
tion of the bleeding segment by open nephrostomy.20
SUMMARY
Sickle cell trait, although mainly benign, may be associated
with renal manifestations especially hematuria. Papillary
necrosis is the most frequent cause of gross hematuria in
patients with sickle cell trait. A complete work-up including
renal imaging with ultrasound or CT scan should be
performed in all sickle cell patients presenting with
hematuria to evaluate for obstruction, kidney stones, tumors,
and renal infarction. In young patients, CT or MR imaging is
indicated to rule out RMC, a rare but deadly diagnosis
associated with hematuria and sickle cell trait.
Conservative measures should be first attempted
when managing such patients. This includes bed rest,
intravenous hydration, alkalinization of urine, and a
blood transfusion if anemia is present. Ureterosopy with
retrograde pyelography should be performed to confirm
the diagnosis of renal papillary necrosis. A direct uretero-
scopic fulgration or tamponade may be attempted at this
time. If bleeding persists, desmopressin acetate (DDAVPs)
and/or EACA (Amicars) infusion can be attempted as
a next step in management. In our opinion, there is
insufficient experimental data to support the use of oral or
intravenous urea. For refractory cases, renal angiography with
embolization may be attempted, although simultaneous
angiography and ureteroscopy has been reported to be more
successful.
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